Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1170 participants.

Also called NCT02058147

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,170 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02058147
  • EudraCT 2013-003131-30
Main results
  • Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial Diabetes care, 2016-11 DOI, PubMed 27527848 PubMed links an erratum for this paper. Erratum: PMID 28420696
Other papers using this trial's data
  • Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial Diabetes, obesity & metabolism, 2019-08 DOI, PubMed 31124299, PMC6772132 In the PMC Open Access subset under CC BY-NC.
  • Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents Diabetes, obesity & metabolism, 2017-12 DOI, PubMed 28432746, PMC5697595 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Belgium, Canada, Chile, Czechia, Denmark, Estonia, France, Germany, Hungary, Italy, Latvia, Lithuania, Mexico, Poland, Romania, Russia, South Africa, Spain, Sweden, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02058147. Randomized; no masking; primary purpose treatment. Start 2014-02 (registry gives no type); primary completion 2015-06 (actual). Results posted on 2017-02-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM
Acronym
LixiLan-O
Intervention (Drug)
Insulin glargine/lixisenatide Fixed Ratio Combination
Intervention (Drug)
Insulin glargine (HOE901)
Intervention (Drug)
Lixisenatide (AVE0010)
Intervention (Drug)
Metformin
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02058147
Content hash
eeb8b695b21523e0a929d3211bddf872f2901cedd3bfdc8853475c773cc5fe16